Question 1

A 23-year-old man is brought to your clinic by his parents. Over the past year, he has dropped out of college, stopped seeing friends, and spends most days in his room. His hygiene has declined. He speaks in short, vague sentences and shows almost no emotional expression. He denies hearing voices. He denies paranoia. His parents say he "isn't the same person." His urine drug screen is negative. What should you be thinking?

Accepted Answer

The progressive functional decline, social withdrawal, flat affect, and poverty of speech over 12 months — in a young male during the peak age of onset — require further evaluation for a psychotic disorder. The absence of positive symptoms does not rule out schizophrenia. Negative symptoms and cognitive decline can precede or exist without prominent positive symptoms. Screen for subtle psychotic experiences (unusual beliefs, perceptual disturbances, ideas of reference) using open-ended questions, not just "do you hear voices?" The key error is assuming depression because the patient denies hallucinations — this is exactly how Patient C in the clinical picture gets misdiagnosed.

Question 2

A 30-year-old woman with a 6-year history of schizophrenia is stable on paliperidone 9mg daily. Her voices are minimal and she lives semi-independently. At her routine visit, you notice she has gained 35 pounds since starting paliperidone, her fasting glucose is 118 mg/dL (pre-diabetic range), and her LDL cholesterol is elevated. She says the medication "saved her life" and doesn't want to change it. What do you do?

Accepted Answer

In schizophrenia, a stable antipsychotic response is precious and should not be abandoned lightly. This requires a collaborative, informed conversation — not a unilateral medication change. Her schizophrenia is well-controlled on paliperidone, which is clinically significant. Abruptly switching risks psychotic relapse. The approach: (1) Address metabolic risk directly with metformin, dietary counseling, and physical activity. (2) Monitor fasting glucose, HbA1c, lipid panel, and weight quarterly. (3) Discuss the long-term metabolic risk honestly so she can make an informed decision. (4) If metabolic syndrome worsens despite intervention, then collaboratively consider a gradual cross-taper to a more metabolically neutral agent (aripiprazole, ziprasidone, lurasidone) with close psychiatric monitoring. Manage the metabolic complications aggressively while maintaining psychiatric stability.

Question 3

A 27-year-old man with schizophrenia has been hospitalized twice in the past year for psychotic relapse. Each time, he stopped taking his oral aripiprazole because "I feel fine and I don't need it." Between episodes, he acknowledges he has schizophrenia but says he "just forgets" or "doesn't see the point" of daily medication. His mother is exhausted. What is the most appropriate intervention?

Accepted Answer

This patient has demonstrated a clear pattern: intact insight between episodes, medication discontinuation, and psychotic relapse. Oral medication has failed not because of inadequate dose or wrong agent, but because of the adherence gap. A long-acting injectable antipsychotic (such as aripiprazole lauroxil or paliperidone palmitate) removes the daily decision point and provides consistent antipsychotic coverage. This should be framed to the patient not as punishment for non-adherence but as a tool that protects the stability he values when he's well. Non-adherence is the most common cause of relapse in schizophrenia, and LAIs address this directly. They should be offered early, not reserved as a last resort after multiple relapses.

Schizophrenia

Red Flags & Key Clinical Considerations

Suicide Risk

Delirium Masquerading as Psychotic Exacerbation

Non-Adherence and Relapse

Metabolic Syndrome

Treatment Resistance — Delayed Clozapine

Related Medications

References & Further Reading